Compare AbCellera Biologics Inc (ABCL) vs Brunswick Corporation (BC) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

BC trades at $77.33, down 2.23% today, with a bearish technical signal and mixed earnings history. Revenue declined to $5.36B in 2025 with a net loss of $137.30M, though recent quarters beat expectations. The company maintains strong analyst support with a $86.40 consensus target and announced a $0.44 dividend for H1-26. Cash flow improved to a near-neutral -$11M in 2025 from deeper losses in prior years.

Outlook is cautious due to profitability challenges and high P/E of 73.92, but expansion news like Freedom Boat Club's 450th location offers growth potential. Risks include sustained negative margins and debt levels, while institutional buy ratings suggest confidence in a turnaround if execution improves.